How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation

Jordan K. Schaefer, Robert D. McBane, Waldemar E. Wysokinski

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The novel oral anticoagulants or direct oral anticoagulants (DOAC) are becoming more common in clinical practice for the prevention of stroke in non-valvular atrial fibrillation (NVAF). The availability of several agents with similar efficacy and safety for stroke prevention in NVAF patients offers more selection, but at the same time requires certain knowledge to make a good choice. This comparative analysis provides an appraisal of the respective clinical trials and highlights much of what remains unknown about four FDA-approved agents: dabigatran, apixaban, rivaroxaban, and edoxaban. It details how the DOACs compare to warfarin and to one another summarizes pharmacologic and pharmacodynamic properties, and drug interactions from the stand point of practical consequences of these findings. Common misconceptions and reservations are addressed. The practical application of this data is intended to help choosing the most appropriate agent for individual NVAF patient.

Original languageEnglish (US)
Pages (from-to)437-449
Number of pages13
JournalAnnals of Hematology
Volume95
Issue number3
DOIs
StatePublished - Feb 1 2016

Fingerprint

Anticoagulants
Atrial Fibrillation
Stroke
Warfarin
Drug Interactions
Clinical Trials
Safety
edoxaban
apixaban
Dabigatran
Rivaroxaban

Keywords

  • Apixaban
  • Dabigatran
  • Direct thrombin inhibitors
  • Factor Xa inhibitors
  • Nonvalvular atrial fibrillation
  • Rivaroxaban
  • Warfarin

ASJC Scopus subject areas

  • Hematology

Cite this

How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. / Schaefer, Jordan K.; McBane, Robert D.; Wysokinski, Waldemar E.

In: Annals of Hematology, Vol. 95, No. 3, 01.02.2016, p. 437-449.

Research output: Contribution to journalArticle

Schaefer, Jordan K. ; McBane, Robert D. ; Wysokinski, Waldemar E. / How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. In: Annals of Hematology. 2016 ; Vol. 95, No. 3. pp. 437-449.
@article{44063072bc094cf8b7a8dda22a0db4a1,
title = "How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation",
abstract = "The novel oral anticoagulants or direct oral anticoagulants (DOAC) are becoming more common in clinical practice for the prevention of stroke in non-valvular atrial fibrillation (NVAF). The availability of several agents with similar efficacy and safety for stroke prevention in NVAF patients offers more selection, but at the same time requires certain knowledge to make a good choice. This comparative analysis provides an appraisal of the respective clinical trials and highlights much of what remains unknown about four FDA-approved agents: dabigatran, apixaban, rivaroxaban, and edoxaban. It details how the DOACs compare to warfarin and to one another summarizes pharmacologic and pharmacodynamic properties, and drug interactions from the stand point of practical consequences of these findings. Common misconceptions and reservations are addressed. The practical application of this data is intended to help choosing the most appropriate agent for individual NVAF patient.",
keywords = "Apixaban, Dabigatran, Direct thrombin inhibitors, Factor Xa inhibitors, Nonvalvular atrial fibrillation, Rivaroxaban, Warfarin",
author = "Schaefer, {Jordan K.} and McBane, {Robert D.} and Wysokinski, {Waldemar E.}",
year = "2016",
month = "2",
day = "1",
doi = "10.1007/s00277-015-2566-x",
language = "English (US)",
volume = "95",
pages = "437--449",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation

AU - Schaefer, Jordan K.

AU - McBane, Robert D.

AU - Wysokinski, Waldemar E.

PY - 2016/2/1

Y1 - 2016/2/1

N2 - The novel oral anticoagulants or direct oral anticoagulants (DOAC) are becoming more common in clinical practice for the prevention of stroke in non-valvular atrial fibrillation (NVAF). The availability of several agents with similar efficacy and safety for stroke prevention in NVAF patients offers more selection, but at the same time requires certain knowledge to make a good choice. This comparative analysis provides an appraisal of the respective clinical trials and highlights much of what remains unknown about four FDA-approved agents: dabigatran, apixaban, rivaroxaban, and edoxaban. It details how the DOACs compare to warfarin and to one another summarizes pharmacologic and pharmacodynamic properties, and drug interactions from the stand point of practical consequences of these findings. Common misconceptions and reservations are addressed. The practical application of this data is intended to help choosing the most appropriate agent for individual NVAF patient.

AB - The novel oral anticoagulants or direct oral anticoagulants (DOAC) are becoming more common in clinical practice for the prevention of stroke in non-valvular atrial fibrillation (NVAF). The availability of several agents with similar efficacy and safety for stroke prevention in NVAF patients offers more selection, but at the same time requires certain knowledge to make a good choice. This comparative analysis provides an appraisal of the respective clinical trials and highlights much of what remains unknown about four FDA-approved agents: dabigatran, apixaban, rivaroxaban, and edoxaban. It details how the DOACs compare to warfarin and to one another summarizes pharmacologic and pharmacodynamic properties, and drug interactions from the stand point of practical consequences of these findings. Common misconceptions and reservations are addressed. The practical application of this data is intended to help choosing the most appropriate agent for individual NVAF patient.

KW - Apixaban

KW - Dabigatran

KW - Direct thrombin inhibitors

KW - Factor Xa inhibitors

KW - Nonvalvular atrial fibrillation

KW - Rivaroxaban

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=84957428412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957428412&partnerID=8YFLogxK

U2 - 10.1007/s00277-015-2566-x

DO - 10.1007/s00277-015-2566-x

M3 - Article

C2 - 26658769

AN - SCOPUS:84957428412

VL - 95

SP - 437

EP - 449

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 3

ER -